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A higher prevalence of solid tumours in patients with M(onoclonal) proteinaemia without a co-existing haematological malig-
nancy has been reported. We investigated this association by linking a population-based registry of patients with newly diagnosed
M-proteinaemia (n ¼ 1464) with the Regional Cancer Registry. Patients were followed for a median of 7.4 years for those still alive.
In total 167 (11%) patients with 173 solid tumours were compared with 861 patients with ‘M-proteinaemia only’ (without a hae-
matological malignancy). The M-protein isotype or level or clinical parameters did not diﬀer between the groups. M-protein isotype
was not associated with a speciﬁc tumour type. Standardised Morbidity Ratios (SMR) for nearly all solid tumours were elevated in
the year of the M-protein discovery, but the excess risk disappeared during follow-up suggesting selection through diagnostic in-
vestigations rather than a causal role. In this large series of patients with both newly diagnosed M-proteinaemia and a solid tumour
no relationship could be established.
 2004 Elsevier Ltd. All rights reserved.
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For many decades, it has been assumed that in pa-
tients with monoclonal (M)-proteinaemia and without
any evidence of a co-existing haematological malig-
nancy, the prevalence of solid tumours is increased
suggestive of a causal relationship [1–8]. Further ana-
lysis of this relationship could determine more exactly
the incidence of this phenomenon in patients with a solid
tumour and vice versa, thereby establishing the rele-
vance of screening in cases of M-proteinaemia. To this
end we linked a Dutch population-based M-protein
database [9,10] to the regional cancer registry, and
compared solid tumour M-protein patients with other
groups in order to try to establish a time relationship
between both diagnoses.* Corresponding author. Tel.: +31-50-3612354; fax: +31-50-3614862.
E-mail address: j.c.kluin-nelemans@int.azg.nl (J.C. Kluin-Nele-
mans).
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2.1. Patient population
From 1991 until 1993, a population-based registry on
M-proteinaemia was set up in the region of the Com-
prehensive Cancer Center West (CCCW), a geographi-
cal area with 1.6 million inhabitants. Clinical chemists,
internists, haematologists, pathologists and other phy-
sicians reported all patients with newly diagnosed
M-proteinaemia or multiple myeloma in the CCCW
area. Information on patients characteristics, laboratory
test results, and results of bone marrow examinations
and skeletal X-rays were documented. The M-protein-
related diagnosis, co-morbidity and therapy were re-
corded. Follow-up was done annually. At follow-up,
clinical data, any evolution into a haematological ma-
lignancy, appearance of any solid tumour, M-protein
levels and other relevant laboratory tests were collected
from the patients’ hospital charts or from the general
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The setup and contents of this registry have been de-
scribed previously in [9,10].
2.2. Diagnostic criteria for monoclonal proteinaemia and
solid tumours
M-proteins were detected either by agarose or by
cellulose acetate electrophoresis, depending on the
method used in the various hospitals involved. For in-
clusion in the registry, each M-protein had to be con-
ﬁrmed by immunotyping (immunoﬁxation). The
presence of a solid tumour preferably had to be con-
ﬁrmed by histology, otherwise a clinical diagnosis had to
be based on at least radiological evidence of a tumour.
Cancer sites were grouped according to the World
Health Organization’s International Classiﬁcation of
Diseases for Oncology (ICD-O) [11].
2.3. Linkage to the regional cancer registry
For veriﬁcation and to ensure the completeness of
our data on solid tumours, the database was linked to
the regional database of the Netherlands Regional
Cancer Registry [12]. In this cancer registry, all pa-
tients with newly diagnosed malignancies living in the
CCCW region reported by the pathology laboratories
are entered. The date of the cytological or histological
conﬁrmation constitutes the date of diagnosis. In
addition, all hospitals employ a separate registry of
the discharge diagnoses. For the present study,
patient data were linked if the name, gender and
date of birth were identical in both databases to ex-
clude the probability of false-positive or false-negative
linkages.
2.4. Solid tumour prevalence and incidence analysis
Follow-up started at registration (between 1991 and
1993) and is still ongoing. For the solid cancer linkage
study, complete coverage with the Regional Cancer
Registry was guaranteed until January 1st 1998. End-
points were the development of a (haematological) ma-
lignancy or death, and patients still alive were censored
for all other events on January 1st 2002. First, the
prevalence of a solid tumour at ﬁrst diagnosis was cal-
culated. Patients were diagnosed with a M-protein-re-
lated solid tumour if the tumour was diagnosed within
the timeframe of two years, one year preceding or fol-
lowing the discovery of the M-protein. Thus, all malig-
nancies that could be associated with the M-protein, but
were not present anymore due to treatment were in-
cluded, as well as any asymptomatic multiple myeloma
(MM), other haematological malignancies or solid tu-
mours that developed later on. In cases of a simulta-
neous haematological malignancy or solid tumourduring this period, the M-protein was considered to
be associated with the former and not with the solid
tumour.
Secondly, Standardised Morbidity Ratios (SMR) for
the most prevalent tumours were determined for the
period between registration (1991–1993) until January 1,
1998. Patients with newly diagnosed M-proteinaemia
were at risk until the diagnosis of a solid tumour, mul-
tiple myeloma, other haematological malignancy was
made or until they died. Multiplication of person-years
under observation by the age-, gender-, and period-
speciﬁc incidence rates yielded the number of solid tu-
mours expected in the M-protein cohort if they experi-
enced the same risk as was prevalent in the region of the
CCCW. With this method, standardised incidence rates
between patient and reference group were compared
(indirect standardisation) and expressed as the ratio of
the incidence rates (SMR), which may be viewed as a
relative risk. Conﬁdence limits for the SMR were based
on a Poisson distribution for the observed number of
deaths [13].
2.5. Statistical methods
Statistical methods to compare the ‘M-proteinaemia
Only’ versus ‘Solid tumour group’ included Mann-
Whitney’s test and in the case of a case-control design,
the chi-square test when appropriate. Analyses were
performed using Statistical Package for the Social Sci-
ences (SPSS) version 10. Data were entered in the da-
tabase using SPSS Data Entry version 2 (both SPSS Inc.
Chicago, IL, USA).3. Results
3.1. Prevalence of solid tumours at ﬁrst diagnosis of
M-proteinaemia
The database consisted of 1464 patients with an
initial diagnosis of M-proteinaemia. The frequency of
newly discovered cases was 31/100,000 inhabitants and
189/100,000 for people above 70 years of age [9]. In
271 patients, a diagnosis of multiple myeloma was
made, in 164 another haematological malignancy was
diagnosed, but in the large majority no explanation
was found (provisional [9] or deﬁnite monoclonal
gammopathy of unknown signiﬁcance, MGUS),
(Table 1).
In total, 173 solid tumours without any evidence of
multiple myeloma or other haematological malignancy
were diagnosed in 167 (11%) patients. The types of tu-
mour found are depicted in Fig. 1. Nearly all tumours
(n ¼ 167; 97%) were (adeno)carcinomas, the other six
malignancies consisted of melanomas (n ¼ 4), leiomyo-
sarcoma (n ¼ 1) and sarcoma (n ¼ 1).
Table 1
Clinical characteristics in all diagnostic groups with M-proteinaemia
Monoclonal proteinaemia
only/MGUS
Solid tumour P -value Multiple myelomaa Other haematological
malignancies b
Number (%) 861 (59) 167 (11) 271 (19) 165 (11)
Gender M (%) 423 (49) 103 (62) 0.004 138 (51) 96 (58)
F (%) 438 (51) 64 (38) 133 (49) 69 (42)
Median age
(range, years)
73 (17–103) 75 (37–95) 0.05 71 (28–93) 72 (21–94)
M 72 (20–103) 75 (37–95) 0.03 69 (28–89) 70 (20–89)
F 75 (17–98) 76 (47–92) 0.91 72 (40–93) 73 (25–94)
M-protein type
and level (g/l)
IgG (%) 618 (72) 29 (76) 0.45 155 (57) 75 (46)
Median (range) 10 (1–30) 10.5 (<1–85) 32.5 (6–117) 12.3 (<1–34)
IgA (%) 80 (9) 10 (6) 0.71 75 (28) 5 (3)
Median (range) 8.4 (4–31) 10 (2–47) 28.1 (5–81) 15.6 (2–25)
IgM (%) 159 (19) 30 (18) 0.19 4 (2) 81 (49)
Median (range) 7 (1–21) 10 (<1–30) 22 (2–57) 13.8 (2–110)
In the patient with prostate carcinoma, two haematological malignancies were observed: chronic lymphocytic leukaemia (CLL) and Hodgkin’s
lymphoma.
M, male; F, female; MGUS, monoclonal gammopathy of unknown signiﬁcance.
a In ﬁve patients, a solid tumour was present (carcinoma of lung, breast, thyroid, ovary and unknown primary site).
b In eight patients, a solid tumour was present (melanoma, carcinoma of unknown primary site, bladder, prostate, colon, larynx, skin and liver).
Fig. 1. Distribution of solid tumours and M-proteinaemia. Two tumours were diagnosed in six patients: bilateral breast (2), breast + pancreas,
breast + colon leiomyosarcoma, squamous skin+melanoma, pancreas + gingiva. No percentage between brackets means only one tumour found.
Modiﬁed from [19].
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To study whether speciﬁc tumour types were related
to speciﬁc M-protein isotypes, we selected patients with
one the six most frequently occurring solid tumours,
lung (n ¼ 40), colon (n ¼ 21), breast (n ¼ 15), prostate
(n ¼ 13), ureter and bladder (n ¼ 10) and pancreas
(n ¼ 9). In all, the IgG isotype predominated (60–85%),
followed by IgM (7–30%) and IgA (0–10%). No clear
preferential M-protein types were seen within the spe-
ciﬁc tumour groups.
3.3. ‘Solid tumour group’ versus ‘M-proteinaemia only
group/MGUS’
To study whether patients with M-proteinaemia and
a solid tumour (i.e. ‘‘Solid tumour Group’’) had speciﬁc
characteristics in demographics or M-protein isotype
and levels, we compared this group with the patients
without any malignancy (Table 1). In the tumour group,
male gender predominated. In addition, small, but sig-
niﬁcant, diﬀerences in age were seen. The distribution of
M-protein isotypes and levels was identical with most
patients expressing a median of approximately 10 g/l
IgG monoclonal proteinaemia.
3.4. Response of the M-protein on cancer treatment
When M-proteins are causally related to a solid
tumour, one would expect to ﬁnd an increase of the
M-protein levels during tumour progression and a
decrease after tumour disappearance. In the Solid
tumour group, 64 out of 167 patients died within oneTable 2
Standardised morbidity ratios (SMR) for the most prevalent solid tumours
Solid tumour (all (adeno)
carcinomas)
Year of M-protein discovery (1991–1993)
Observed
number
Expected
number
SMR 95% Co
interval
Men
Lung 19 0.9 21.1 12.5–31
Colon and rectosigmoid 4 0.4 10 2.5–22.5
Prostate 5 0.9 5.6 1.7–11.6
Unknown primary 5 0.2 25 7.6–52.4
Pancreas 1 0.1 10 0–40
Stomach 2 0.3 6.7 0.6–19.4
Bladder 3 0.2 15 2.7–37.3
Women
Lung 3 0.1 30 5.4–74.6
Colon and rectosigmoid 4 0.4 10 2.5–22.5
Breast 3 0.6 5 0.9–12.4
Unknown primary 5 0.1 50 15.2–10
Pancreas 4 0.1 40 10–90
Stomach 2 0.1 20 1.7–58.3
Bladder 0 0.1 0 0–40year after the detection of the M-protein leaving 103
patients with follow-up data. In 25 patients (median
follow-up 37 months, range 3–95 months) the M-
protein was measured at least once after the ﬁrst de-
tection and therapy (if any) for the solid tumour. Since
in four patients a haematological malignancy devel-
oped (see Section 3.5), a relationship (rising or low-
ering of the M-protein in correspondence with the
progression or decrease of the tumour) could be
studied only in 21 patients. In this small group of
patients, no convincing relationship was seen between
the behaviour of the solid tumour and M-protein
levels (data not shown).
3.5. Follow-up since entry in the M-protein database
During follow up (last analysis 1-1-2002) a new solid
tumour was detected in 23 patients in addition to those
already diagnosed in the 167 patients. All of these tu-
mours occurred in the period 1992–1998 (see Table 2).
In the years thereafter, no additional solid tumours were
found. Out of the 167 patients in whom a solid tumour
was diagnosed simultaneously with the M-protein, three
patients developed multiple myeloma (14, 56 and 65
months after the detection of the M-protein) and one
patient developed a non-Hodgkin’s lymphoma (NHL)
(28 months after the detection of the M-protein).
For comparison, in the Monoclonal proteinaemia
only/MGUS group, 28 developed multiple myeloma,
and another 17 developed a haematological malignan-
cies, consisting of a NHL (n ¼ 12), myelodysplastic
syndrome or acute myeloid leukaemia (n ¼ 3) or mye-
loproliferative disease (n ¼ 2).in the year of discovery of the M-protein and the years after
Follow-up (1992–1998)
nﬁdence Observed
number
Expected
number
SMR 95% Conﬁdence
interval
.9 5 4.1 1.2 0.4–2.6
1 1.7 0.6 0–2.4
3 4.5 0.7 0.2–1.7
2 0.8 2.5 0.2–7.3
0 0.25 0 0–4
0 0.8 0 0–1.3
1 1.0 1 0–4.0
0 0.6 0 0–1.7
5 1.6 3.1 1.0–6.5
3 2.9 1.0 0.2–2.6
4.7 2 0.6 3.3 0.3–9.7
2 0.4 5.0 0.4–14.6
0 0.7 0 0–1.4
1 0.29 3.5 0–13.8
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Cumulative follow-up of all 1464 patients during this
selected period (1991–1998) was 3060 person-years with
a median follow-up of 1.3 years (range 0–7 years) for all
patients, and a median follow-up of 7.4 years (range 10
months to 11 years) for those still alive. Cumulative
follow-up (measuring the time interval between the date
of diagnosis of the M-proteinaemia and the date of di-
agnosis of the solid tumour) for the Solid tumour group
was 24 person-years (median less than 1 day, range
0–2.8 years). In conclusion, most solid tumours were
diagnosed simultaneously with the detection of the
M-protein (median interval between both diagnoses less
than one day, see above). In the ﬁrst year after the de-
tection of the M-protein, SMR for nearly all solid tu-
mours showed an increased risk (range 0–50). However,
all declined sharply or normalised during the subsequent
follow-up years (Table 2).4. Discussion
In this population-based registry on patients with
newly diagnosed M-proteinaemia, we describe the
largest series collected thus far of patients with both a
solid tumour and a M-protein, but without any evi-
dence of a co-existing haematological malignancy.
Since 1928, investigators have reported an increased
prevalence of solid tumours in patients with M-pro-
teinaemia suggesting a paraneoplastic phenomenon.
For comparison with our cohort, we selected only
studies with more than 100 patients, with a description
of the related malignancy including concise histopa-
thology and information on the determination of the
M-protein, and were left with 8 [1–8]. Identical to our
series, nearly all solid tumours described were (ad-
eno)carcinomas. M-proteins were mostly of the IgG
isotype and levels (if investigated) were generally lower
than 30 g/l.
The co-existing tumours in this M-protein database
were manifest at the diagnosis of the M-protein in the
large majority of patients. During follow-up, only a
small additional number of solid tumours were detected.
Kyle and colleagues observed the development of a
second tumour in 15 of 241 MGUS-patients during a
20–35 year follow-up [14] and Pasqualetti and colleagues
reported 31 out of 263 similar patients who died due to a
solid tumour during a median follow-up of 11.5 years
[15]. In contrast, in the only prospective study investi-
gating the incidence of hematological and solid malig-
nancies in patients with M-proteinaemia, Gregersen and
colleagues did not observe an increased risk of solid
tumours in 1229 patients during follow-up (mean 4.8
years, range 0–15.7 years) [16]. Similar to our ﬁndings,
the risk of developing a solid tumour was increased inthe ﬁrst year of follow-up, although this risk diminished
thereafter [16].
Approaching the probable relationship between
M-proteinaemia and cancer the other way around yielded
no association either: in two cross-sectional studies, the
prevalence of M-proteinaemia in patients with non-hae-
matological tumours was not increased when compared
with the prevalence in the general population [17,18].
In conclusion, we did not observe diﬀerences in clin-
ical characteristics between patients with ‘M-proteina-
emia only/MGUS’ and patients with ‘Solid tumour and
M-proteinaemia’. There was no relationship between
speciﬁc solid tumours and M-protein isotype nor did the
serum level of the M-protein change after the anti-tu-
mour therapy (although the number of patients was
small in this analysis). Although risks for nearly all solid
tumours found were initially elevated in patients with
newly diagnosed M-proteinaemia, these decreased in the
year after suggesting a diagnostic selection of patients
rather than a causal role.Acknowledgements
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